ClinicalTrials.gg
CompletedNCT00877903Updated Mar 11, 2026

Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

A Phase 2 interventional study of Prochymal® and Placebo in Myocardial Infarction, sponsored by Mesoblast, Inc.. Completed at 33 sites in 2 countries. Open to participants aged 21 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Mesoblast, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2011, 15 years 5 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2021.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
21 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 440 studies in Myocardial Infarction with a site in United States — 41 open to participants now, 65 under way, 9 of them phase 3. Myocardial Infarction · United States.

Enrollment
132nd of 301
220 · median 160
Started
2009
with 17 others
Phase 2
38 of 440
5 open now
Registered
155th of 440
by date

Among the 440 studies in Myocardial Infarction with a site in United States, this one is the 132nd largest by enrollment of the 301 interventional ones that give a count, is one of 18 that started in 2009, is one of 38 in phase 2, and was the 155th registered.

Myocardial Infarction

2,274 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

41 of the 440 studies in Myocardial Infarction with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 21 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Myocardial Infarction with a site in United States, or all of them as a file.
02

Study summary

The objective of the present study is to establish the safety and efficacy of Prochymal® following first acute myocardial infarction.

Read the detailed description

The standard of care treatment for acute myocardial infarction (AMI) usually includes immediate perfusion, optimal pain relief, oxygen, aspirin or other anti-coagulants, Beta-Blockers, nitrates and Ace-inhibitors. However, because salvaging the viable myocardium is dependent on early reperfusion, only a minority of participants will reach the hospital within the time-window for myocardial rescue. Thus, even if the participant manages their tobacco use, hypertension, lipid levels, diabetes, weight and exercise, many participants will go on to develop Congestive Heart Failure (CHF). Though the medical management for CHF may improve symptoms and slow disease progression, such treatment cannot restore a functioning myocardium. A therapy that could improve the myocardial remodeling process and reduce the incidence or severity of CHF following acute MI would provide a significant benefit. The characteristics and biologic activity of Prochymal®, along with a good safety profile in human trials to date, suggest that Prochymal® may be a good candidate for addressing this unmet medical need.

03

Conditions studied

  • Myocardial Infarction

Keywords

  • Acute myocardial infarction
  • AMI
  • Myocardial infarction
  • Heart attack
  • Mesenchymal stem cells
  • MSC
  • Adult human stem cells
  • Osiris
04

Who can participate

Ages eligible
21 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 21 and 85 years old, inclusive
  • First heart attack within 7 days prior to randomization and drug infusion
  • Baseline (LVEF) 20-45%
  • Hemodynamically stable within 24 hours prior to randomization
  • Adequate pulmonary function

Exclusion criteria

Exclusion Criteria:

  • Previous medical history of heart attack, heart failure, significant valvular heart disease, aortic dissection
  • Pacemaker or other device
  • Pregnant, breast-feeding, or intends to become pregnant during the study
  • Allergy to cow or pig derived products
  • Evidence of active or prior history of active malignancy
  • Major surgical procedure or major trauma within the past 14 days
  • disease (e.g., Lupus, Multiple Sclerosis)
  • Any medical condition, which in the opinion of the Investigator, renders participation unsuitable
  • Undergone pharmacologic cardioversion or external defibrillation within 24 hours of randomization.
  • Experienced cardiac arrest more than 36 hours after presentation to site or within 24 hours of randomization.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    Prochymal®

    Participants will receive Prochymal® single intravenous (IV) infusion at a dose of 200 x 10\^6 human mesenchymal stem cells (hMSC), reconstituted in 80 mL, delivered at a rate of 2 mL/min, with a maximum rate of 5.0 x 10\^6 hMSC/minute, and the participants will be followed for 24 months and remain in the study for up to 60 months.

    Drug: Prochymal®

  • Placebo comparator
    Placebo

    Participants will receive Prochymal® placebo-matching single IV infusion at a dose of of 200 x 10\^6 hMSC, reconstituted in 80 mL, delivered at a rate of 2 mL/min, with a maximum rate of 5.0 x 10\^6 hMSC/minute, and the participants will be followed for 24 months and remain in the study for up to 60 months.

    Drug: Placebo

Interventions

  • Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells

    Also known as: Remestemcel-L

  • DrugPlacebo

    Intravenous infusion of excipients of Prochymal®

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Cardiac Magnetic Resonance (CMR) imaging-determined End Systolic Volume (ESV) at Month 3

    Time frame: Baseline, Month 3

Secondary outcomes

  1. Left Ventricular End Systolic Volume

    Time frame: 6 months

  2. Infarct Size

    Time frame: 3 and 6 months

  3. Left Ventricular Ejection Fraction

    Time frame: 3 and 6 months

  4. Left Ventricular End Diastolic Volume

    Time frame: 3 and 6 months

  5. Number of Participants with Ventricular Arrhythmias

    Time frame: 3 and 6 months

  6. Duke Activity Status Index (DASI) Assessment

    The Duke Activity Status Index (DASI) is a brief, self-administered questionnaire that provides a standardized assessment of functional status and quality-of-life that correlates well with an objective measure of maximal exercise capacity. The scale ranges from 0 (unable to perform any tasks) to 58.20 (able to perform all tasks). Higher scores indicate a greater ability to perform daily activities.

    Time frame: 6, 12, and 24 months

  7. New York Heart Association (NYHA) Congestive Heart Failure Classification Status

    Time frame: 6, 12, 24, and 60 months

  8. Maximal Symptom-limited Exercise Test (Treadmill)

    Time frame: 6 and 12 months

  9. Number of Participants with Major Adverse Cardiac Events (MACE)

    Time frame: 6, 12, 24, and 60 months

  10. Overall Survival

    Time frame: 60 months

  11. Number of Participants with Adverse Events

    Time frame: 3,6,12,24,60 months

07

Study locations

33 sites
  • Mercy Gilbert Medical Center / Catholic Health Care West
    Gilbert, Arizona 85297, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • UC Davis Medical Center
    Sacramento, California 95817, United States
  • University of California - San Diego (UCSD)
    San Diego, California 92103, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Mount Sinai Medical Center
    Miami Beach, Florida 33140, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • The Care Group
    Indianapolis, Indiana 46290, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Cotton-O'Neil Clinical Research Center
    Topeka, Kansas 66604, United States
  • University of Maryland Hospital
    Baltimore, Maryland 21201, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Baystate Medical Center
    Springfield, Massachusetts 01199, United States
  • UMass Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
  • Michigan Cardiovascular Institute
    Saginaw, Michigan 48601, United States
  • Minneapolis Heart Institute
    Minneapolis, Minnesota 55407, United States
  • UMDNJ - Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08903, United States
  • University at Buffalo - Buffalo General Hospital
    Buffalo, New York 14203, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11794, United States
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • The Lindner Research Center
    Cincinnati, Ohio 45219, United States
  • The Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Penn State University - Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Drexel University College of Medicine
    Philadelphia, Pennsylvania 19102, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • The Stern Cardiovascular Center
    Germantown, Tennessee 38138, United States
  • Austin Heart P.A.
    Austin, Texas 78756, United States
  • University of Texas Health Science Center
    Houston, Texas 77030, United States
  • Fletcher Allen Health Care
    Burlington, Vermont 05401, United States
  • University of Wisconsin School of Medicine
    Madison, Wisconsin 53792, United States
  • McGill University Health Centre
    Montreal, Quebec H3A 1A1, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2009 to primary completion in May 2011, 25 months.

Of 45 phase 2 interventional studies under Myocardial Infarction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 42. This study's 25 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2009
First posted
Apr 8, 2009
StartActual
Mar 30, 2009
Primary completionActual
May 18, 2011
CompletionActual
Mar 14, 2016
Results delay requested
Dec 20, 2021
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00877903
Lead sponsor
Mesoblast, Inc.
Responsible party
Sponsor
First posted
Apr 8, 2009
Start date
Mar 30, 2009
Primary completion
May 18, 2011
Completion
Mar 14, 2016
Last update
Mar 11, 2026

Study contacts

Ken Borow, MD
study director · Mesoblast, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remestemcel-l

Start the discussion